Imaging features of hepatic angiosarcoma: retrospective analysis of two centers.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
27 Sep 2024
Historique:
received: 09 03 2024
accepted: 16 08 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

Identifying primary hepatic angiosarcoma (PHA) preoperatively is challenging, often relying on postoperative pathology. Invasive biopsy increases bleeding risk, emphasizing the importance of early PHA diagnosis through imaging. However, comprehensive summaries of ultrasound, abdominal computed tomography (CT), magnetic resonance imaging (MRI), and whole- body positron emission tomography-CT (PET-CT) in this context are lacking. This study aimed to investigate the comprehensive imaging characteristics of PHA. Imaging data were collected from 7 patients diagnosed with PHA via pathology between January 2000 and December 2019 in two provincial grade III hospitals. All patients underwent routine color ultrasound examinations before surgery, with 3 patients receiving contrast-enhanced ultrasound (CEUS).CT scans, both plain and enhanced, were performed on 5 patients, and whole-body PET-CT examinations were conducted on 2 patients. Among the 7 patients with PHA, 4 presented with a single solid intrahepatic mass (2 of which were large), 1 with a single exophytic macroblock type, 1 with a mixed type featuring multiple masses and nodules, and 1 with a multiple nodule type. Conventional ultrasound of PHA showed uneven echoes within the tumor, potentially accompanied by septal zone echoes, and a blood flow grade of 0-I. CEUS displayed early-stage circular high enhancement, a central non-enhancement area, and a "vascular sign" around the tumor. CT scans revealed low-density shadows in the plain scan stage, high peripheral ring enhancement, and punctate nodular enhancement in the arterial phase, with varying intensities and the presence of a "vascular sign." During the portal vein stage, the interior of the tumor was consistently unfilled and exhibited structural disorder. PET-CT showed low-density lesions in the liver and low fluorodeoxyglucose metabolism. Imaging diagnosis plays a crucial role in PHA diagnosis. When liver tumor imaging matches the above characteristics, consider PHA.

Identifiants

pubmed: 39333917
doi: 10.1186/s12885-024-12817-2
pii: 10.1186/s12885-024-12817-2
doi:

Substances chimiques

Contrast Media 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1191

Subventions

Organisme : Fujian Provincial Science and Technology Plan Guiding Project Fund
ID : 2022Y0013
Organisme : High-Level Medical Care Construction Foundation Of Fujian Province
ID : [2021]76

Informations de copyright

© 2024. The Author(s).

Références

Molina E, Hernandez A. Clinical manifestations of primary hepatic angiosarcoma. Dig Dis Sci. 2003;48:677–82.
doi: 10.1023/A:1022868221670 pubmed: 12741455
Mehrabi A, Kashfi A, Fonouni H, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer. 2006;107:2108–21.
doi: 10.1002/cncr.22225 pubmed: 17019735
Astolfi A, Nannini M, Indio V, et al. Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. Cancers (Basel). 2020;12(8):2126.
doi: 10.3390/cancers12082126 pubmed: 32751892
Rizzo A, Nannini M, Astolfi A, et al. Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis. Cancers (Basel). 2020;12(7):1899.
doi: 10.3390/cancers12071899 pubmed: 32674439
Adler DD, Carson PL, Rubin JM, Quinn-Reid D. Doppler ultrasound color flow imaging in the study of breast cancer: preliminary findings. Ultrasound Med Biol. 1990;16(6):553–9.
doi: 10.1016/0301-5629(90)90020-D pubmed: 2238263
Jiang L, Xie L, Li G, et al. Clinical characteristics and surgical treatments of primary hepatic angiosarcoma. BMC Gastroenterol. 2021;21:156.
doi: 10.1186/s12876-021-01743-3 pubmed: 33827427 pmcid: 8028144
Yi LL, Zhang JX, Zhou SG, et al. CT and MRI studies of hepatic angiosarcoma. Clin Radiol. 2019;74(5):406.e1-406.e8.
doi: 10.1016/j.crad.2018.12.013 pubmed: 30686504
Zhou Z, Lu X, Wang W, Yang J. Hepatic Angiosarcoma With Diffuse Increased 18 F-FDG Uptake on PET/CT. Clin Nucl Med. 2022;47:817–9.
doi: 10.1097/RLU.0000000000004152 pubmed: 35383600
Zheng YW, Zhang XW, Zhang JL, et al. Primary hepatic angiosarcoma and potential treatment options. J Gastroenterol Hepatol. 2014;29:906–11.
doi: 10.1111/jgh.12506 pubmed: 24372769
Locker GY, Doroshow JH, Zwelling LA, Chabner BA. The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature. Medicine (Baltimore). 1979;58:48–64.
doi: 10.1097/00005792-197901000-00003 pubmed: 368508
Groeschl RT, Miura JT, Oshima K, et al. Does histology predict outcome for malignant vascular tumors of the liver? J Surg Oncol. 2014;109:483–6.
doi: 10.1002/jso.23517 pubmed: 24284733
Noguchi K, Nakashima O, Nakashima Y, et al. Clinicopathologic study on hepatocellular carcinoma negative for hepatitis B surface antigen and antibody to hepatitis C virus. Int J Mol Med. 2000;6:661–5.
pubmed: 11078825
Ling W, Qiu T, Ma L, et al. Contrast-enhanced ultrasound in diagnosis of primary hepatic angiosarcoma. J Med Ultrason. 2001;2017(44):267–70.
Gulmez AO, Aydin S, Kantarci M. A complementary comment on primary hepatic angiosarcoma: A case report. World J Clin Cases. 2023;11:1814–22.
doi: 10.12998/wjcc.v11.i8.1814 pubmed: 36969989 pmcid: 10037275
Trojan J, Hammerstingl R, Engels K, et al. Contrast-enhanced ultrasound in the diagnosis of malignant mesenchymal liver tumors. J Clin Ultrasound. 2010;38:227–31.
doi: 10.1002/jcu.20690 pubmed: 20336772
Wang J, Sun LT. Primary hepatic angiosarcoma: A case report. World J Clin Cases. 2022;10:11590–6.
doi: 10.12998/wjcc.v10.i31.11590 pubmed: 36387808 pmcid: 9649549
Corvino A, Catalano O, Corvino F, et al. Diagnostic performance and confidence of contrast-enhanced ultrasound in the differential diagnosis of cystic and cysticlike liver lesions. AJR Am J Roentgenol. 2017;209:W119–27.
doi: 10.2214/AJR.16.17062 pubmed: 28639831
Corvino A, Sandomenico F, Setola SV, et al. Morphological and dynamic evaluation of complex cystic focal liver lesions by contrast-enhanced ultrasound: current state of the art. J Ultrasound. 2019;22:251–9.
doi: 10.1007/s40477-019-00385-2 pubmed: 31087277 pmcid: 6704192
Hanafusa K, Ohashi I, Himeno Y, et al. Hepatic hemangioma: findings with two-phase CT. Radiology. 1995;196:465–9.
doi: 10.1148/radiology.196.2.7617862 pubmed: 7617862
Koyama T, Fletcher JG, Johnson CD, et al. Primary hepatic angiosarcoma: findings at CT and MR imaging. Radiology. 2002;222:667–73.
doi: 10.1148/radiol.2223010877 pubmed: 11867783

Auteurs

Lei Jiang (L)

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.
Key Laboratory of The Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.
Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.

Lijun Xie (L)

Department of Ultrasonic Image, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, Fujian Province, China.
Department of Ultrasonic Image, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, Fujian Province, China.

Zhenheng Wu (Z)

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.
Key Laboratory of The Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.
Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.

Qiming Ke (Q)

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.
Key Laboratory of The Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.
Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.

Mo Chen (M)

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.
Key Laboratory of The Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.
Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.

Wei Pan (W)

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.
Key Laboratory of The Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.
Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.

Fuxiu Zhong (F)

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.
Department of Hepatobiliary Surgery Nurse, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.

Haijie Hong (H)

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.
Key Laboratory of The Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.
Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.

Jiangzhi Chen (J)

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.
Key Laboratory of The Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.
Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.

Xinran Cai (X)

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.
Key Laboratory of The Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.
Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.

Shun Chen (S)

Department of Ultrasonic, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China.

Ling Gan (L)

Department of Ultrasonic Image, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, Fujian Province, China. linggan_1129@fjmu.edu.cn.
Department of Ultrasonic Image, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, Fujian Province, China. linggan_1129@fjmu.edu.cn.

Yanling Chen (Y)

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China. drchenyl@126.com.
Key Laboratory of The Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, 350108, Fujian Province, China. drchenyl@126.com.
Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, 350108, Fujian Province, China. drchenyl@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH